Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye

Oxurion NV to Present at H.C. Wainwright & Co 22nd Annual Global Investment Conference

14 Sep 2020

Leuven, Belgium, 14 September 2020 – 8.00 A.M. CET – Oxurion NV (Euronext Bxls: OXUR), a biopharmaceutical company developing next-generation standard-of-care therapies for diabetic macular edema (DME), announces today that the Company’s CEO, Dr. Patrik De Haes, will be presenting at HC Wainwright & Co’s 22nd Annual Global Investment Conference on Wednesday, September 16th, 2020 at 10:00 a.m. ET.

The presentation will cover Oxurion’s emerging DME franchise designed to improve the treatment outcomes of all DME patients. The Company’s franchise is based around THR-149 and THR-687, two novel drug candidates with different, non-VGEF modes of action. DME is a significant global healthcare problem and the major cause of vision loss in diabetic patients worldwide.  

During the virtual conference, which will take place September 14-16, 2020, Oxurion will also be participating in one-on-one sessions.